References
- 1. Zhang Y, Hu G, Yuan Z, Chen L. Glycosylated hemoglobin in relationship to cardiovascular outcomes and death in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS One. 2012;7:e42551. doi: 10.1371/journal.pone.0042551.10.1371/journal.pone.0042551341542722912709
- 2. Goldenberg I. Inflammatory markers and the risk of recurrent coronary events: the importance of dynamic risk assessment. Cardiol J. 2007;14:11-13.
- 3. Erzen B, Šabovic M, Poredoš P, Šebeštjen M, Keber I, Simcic LS. Inflammation markers in young post-myocardial patients exhibiting various expressions of classic coronary risk factors. Coronary Artery Disease. 2006;17:325-330.10.1097/00019501-200606000-0000116707954
- 4. Nian M, Lee P, Khaper N, Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res. 2004;94:1543-1553. doi: 10.1161/01.RES.0000130526.20854.fa.10.1161/01.RES.0000130526.20854.fa15217919
- 5. Biasucci LM, Liuzzo G, Della Bona R, et al. Different Apparent Prognostic Value of hsCRP in Type 2 Diabetic and Nondiabetic Patients with Acute Coronary Syndromes. Clin Chem. 2009;55:365-368. doi: 10.1373/clinchem.2008.119156.10.1373/clinchem.2008.11915619179271
- 6. Schulze M, Rimm E, Li T, Rifai N. C-reactive protein and incident cardiovascular events among men with diabetes. Diabetes Care. 2004;27:889-894. http://dx.doi.org/10.2337/diacare.27.4.889.10.2337/diacare.27.4.88915047644
- 7. Peterson LR, McKenzie CR, Schaffer JE. Diabetic cardiovascular disease: getting to the heart of the matter. J Cardiovasc Transl Res. 2012;5:436-445. doi: 10.1007/s12265-012-9374-7.10.1007/s12265-012-9374-7339676522639341
- 8. Yorgun H, Canpolat U, Hazırolan T, et al. Increased epicardial fat tissue is a marker of metabolic syndrome in adult patients. Int J Cardiol. 2013;165:308-313. doi: 10.1016/j. ijcard.2011.08.067.
- 9. Harada K, Amano T, Uetani T, et al. Cardiac 64-multislice computed tomography reveals increased epicardial fat volume in patients with acute coronary syndrome. Am J Cardiol. 2011;108:1119-1123. doi: 10.1016/j.amjcard.2011.06.012.10.1016/j.amjcard.2011.06.01221813107
- 10. Yerramasu A, Dey D, Venuraju S, et al. Increased volume of epicardial fat is an independent risk factor for accelerated progression of sub-clinical coronary atherosclerosis. Atherosclerosis. 2012;220:223-230. doi: 10.1016/j. atherosclerosis.2011.09.041.
- 11. Sabatine MS, Morrow DA, Jablonski KA, et al; PEACE Investigators. Prognostic significance of the Centers for Disease Control/American Heart Association highsensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circ. 2007;115:1528-1536. doi: 10.1161/ CIRCULATIONAHA.106.64993910.1161/CIRCULATIONAHA.106.64993917372173
- 12. Soinio M, Marniemi J, Laakso M, Lehto S, Ronnemaa T. Highsensitivity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes. A 7-year followup study. Diabetes Care. 2006;29:329-333. http://dx.doi.org/10.2337/diacare.29.02.06.dc05-1700.10.2337/diacare.29.02.06.dc05-170016443882
- 13. Karaca I, Aydin K, Yavuzkir M, Ilkay E, Akbulut M. Predictive value of C-reactive protein in patients with unstable angina pectoris undergoing coronary stent implantation. J Int Med Res. 2005;33:389-396.10.1177/14732300050330040416104442
- 14. Wilson MW, Marno CR, Andrew JB. The novel role of C reactive protein in cardiovascular disease: risk marker or pathyogen. Int J Cardiol. 2006;106:291-297. doi: http://dx.doi.org/10.1016/j.ijcard.2005.01.068.10.1016/j.ijcard.2005.01.06816337036
- 15. von Bibra H, St John Sutton M. Impact of diabetes on postinfarction heart failure and left ventricular remodeling. Curr Heart Fail Rep. 2011;8:242-251. doi: 10.1007/s11897-011-0070-8.10.1007/s11897-011-0070-8320810021842146
- 16. Swiatkiewicz I, Kozinski M, Magielski P, et al. Usefulness of C-reactive protein as a marker of early post-infarct left ventricular systolic dysfunction. Inflamm Res. 2013;61:725-734. doi: 10.1007/s00011-012-0466-2.10.1007/s00011-012-0466-2337500522446726